"The fourth subject of the third cohort, who was the twelfth and final subject of the phase 1 clinical study, was successfully transplanted with the highest dose of ISC-hpNSC® stem cells."

"Interim results of this study will be presented at the upcoming 2019 American Academy of Neurology 71st Annual Meeting in Philadelphia, PA on May 5th, 2019."

International Stem Cell Corporation Completes Enrollment and Dosing in its Parkinson's Disease Clinical Trial Other OTC:ISCO